IDEAYA Biosciences (IDYA) said Monday it nominated IDE892 as a development candidate, which it said is a potential methylthioadenosine-cooperative PMRT5 inhibitor.
The oncology company said IDE892 has demonstrated "exceptionally selective" antiproliferative activity in MTAP-deleted tumor cell models.
IDEAYA said ongoing studies of IDE892 are intended to support an investigational new drug filing to the U.S. Food and Drug Administration in mid-2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments